|
|
Article: HemoBioTech, Inc. Retains the Investor Relations Group, Inc.
- Article from:
- Business Wire
- Article date:
- October 1, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DALLAS -- HemoBioTech, Inc. (OTC BB: HMBT), a biopharmaceutical company focused on developing the first viable substitute for human blood, has retained the Investor Relations Group, Inc. (IRG), based in New York City, to serve as its financial relations and corporate communications firm.
"With the development of our proprietary technology, HemoTech[TM], aimed at providing a viable substitute for human blood that delivers non-toxic, vasodilatory, anti-inflammatory, and erythropoiesis benefits, we have a tremendous opportunity to address an increasing demand for a safe and inexpensive human blood substitute in the United States and around the world," said Arthur ...
Related newspaper, magazine, and journal articles:
|
|
Article: Advanced BioPhotonics Partners with The Investor ...
Business Wire;
February 16, 2006 ;
700+ words
... ... applications, has contracted The Investor Relations Group ("IRG") of New York ... communications company. The Investor Relations Group will strive to increase ... BioPhotonics, said, "The Investor Relations Group has an impressive track ...
|
|